Opvee patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458091 INDIVIOR Compositions and methods for the treatment of opioid overdose
Jul, 2038

(14 years from now)

Opvee is owned by Indivior.

Opvee contains Nalmefene Hydrochloride.

Opvee has a total of 1 drug patent out of which 0 drug patents have expired.

Opvee was authorised for market use on 22 May, 2023.

Opvee is available in spray;nasal dosage forms.

Opvee can be used as treating opioid overdose.

The generics of Opvee are possible to be released after 10 July, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 22, 2026

Drugs and Companies using NALMEFENE HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2023

Treatment: Treating opioid overdose


More Information on Dosage

OPVEE family patents

Family Patents